Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

0.9427 -0.0233 (-2.41%)
Streaming Delayed Price Updated: 11:51 AM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Fate Therapeutics, Inc. (FATE) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
 
Via Benzinga
FATE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
From Kirby McInerney LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
From Law Offices of Howard G. Smith
Via Business Wire
Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline
From Lowey Dannenberg, P.C.
Via GlobeNewswire
EQUITY ALERT: Rosen Law Firm Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
From The Rosen Law Firm, P.A.
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
5 Health Care Stocks That Are Diving - And May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week. 
Via MarketBeat
Topics Stocks
The Law Offices of Frank R. Cruz Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
Over $10 Million Bet On DiamondHead Holdings? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed higher on Friday, there were a few notable insider trades. 
Via Benzinga
FATE ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Fate Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Top 5 Health Care Stocks That May Surge
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
How Is The Market Feeling About Fate Therapeutics?
Fate Therapeutics's (NASDAQ:FATE) short percent of float has fallen 4.62% since its last report. The company recently reported that it has 20.24 million shares sold short, which is 27.85% of all... 
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest. 
Via InvestorPlace
Dow Jumps 700 Points; S&P 500 Rises Over 2%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.